Merlano Marco, Mattiot Valentina Polla
Department of Clinical Oncology, S. Croce General Hospital, Via M. Coppino 26, 12100 Cuneo, Italy.
Expert Rev Anticancer Ther. 2006 Mar;6(3):395-403. doi: 10.1586/14737140.6.3.395.
Chemoradiation is a standard approach to advanced unresectable head and neck cancer, although the optimum combination regimen remains controversial. However, in the past few years, chemoradiation has been successfully extended from the treatment of unresectable disease to the postsurgical therapy of high-risk patients and its value as an organ preservation procedure is under evaluation. More recently, molecular-targeted therapies have emerged, which interfere with mechanisms of chemo- and radioresistance, and preliminary data are promising. Their use in the combined treatment of head and neck cancer will hopefully further improve the value of chemoradiation in the clinical setting.
尽管最佳联合方案仍存在争议,但放化疗是晚期不可切除头颈癌的标准治疗方法。然而,在过去几年中,放化疗已成功地从不可切除疾病的治疗扩展至高风险患者的术后治疗,其作为一种器官保留程序的价值正在评估中。最近,分子靶向治疗出现了,它干扰化疗和放疗耐药机制,初步数据很有前景。它们在头颈癌联合治疗中的应用有望进一步提高放化疗在临床中的价值。